Patents by Inventor Xingfu Li

Xingfu Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF
    Publication number: 20230026425
    Abstract: Provided are an acylamino bridged heterocyclic compound of formula (I) or a pharmaceutically acceptable salt, an isomer, a solvate, a crystal, or a prodrug thereof, and a pharmaceutical composition comprising the compound, and an application of the compound or composition in drug preparation. The compound and the pharmaceutically acceptable salt, the isomer, the solvate, the crystal, or the prodrug thereof and the like can be used for treatment or prevention of autoimmune diseases, tumors, and neurodegenerative diseases related to receptor-interacting protein kinase-1 (RIPK1).
    Type: Application
    Filed: January 17, 2020
    Publication date: January 26, 2023
    Inventors: Qiang Zhang, Yansheng Liu, Xingfu Li, Shaohua Zhang, Chenming Hu
  • Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
    Patent number: 11479559
    Abstract: The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 25, 2022
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yansheng Liu, Xingfu Li, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
    Patent number: 11344549
    Abstract: The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: May 31, 2022
    Inventors: Qiang Zhang, Yansheng Liu, Lantao Li, Xingfu Li, Chenming Hu
  • 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF
    Publication number: 20210077489
    Abstract: The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers.
    Type: Application
    Filed: September 20, 2018
    Publication date: March 18, 2021
    Inventors: Qiang Zhang, Yansheng Liu, Lantao Li, Xingfu Li, Chenming Hu
  • UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF
    Publication number: 20200399284
    Abstract: The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Application
    Filed: January 25, 2019
    Publication date: December 24, 2020
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yansheng Liu, Xingfu Li, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu